Lung cancer is a malignant tumor with highest morbidity and mortality. Among them, 15% to 20% are SCLC. The incidence rate shows an increasing trend. It is characterized by rapid growth, early metastasis and highly aggressive. Because of its high degree of sensitivity to chemotherapy, chemotherapy is the most important and basic treatment for patients with SCLC. The EP regimen has become the standard first-line treatment for limited stage and extensive stage of SCLC, with efficiency of 60% to 80%. However, due to the fast doubling time, high proliferation and acquired resistance, most patients have recurrence or metastasis in a few months. And IT demonstrates the first line treatment failure. They need further treatment of second-tier program.

So far, recurrence of SCLC second line of evidence based medicine is still very limited for pharmaceutical raw materials suppliers. Six months after starting treatment, drug relapse topotecan, CPT-11, paclitaxel, docetaxel, gemcitabine, gemcitabine, with priority given to participants in clinical trials. In recent years, irinotecan, irinotecan, cisplatin tumor cell lung cancer, with good results, but the unique mechanism of action of irinotecan special effects. Approved by medical practices and training in psychological stress and anxiety in patients that reduces the side effects of chemotherapy in patients with small cell lung cancer cell. In close collaboration with health care, prevention and reduction of chemotherapy side effects to ensure the proper functioning of the effects of chemotherapy and satisfaction.

Chemotherapeutic agents can be used as bone marrow is removed, has decreased significantly in peripheral blood white blood cells, thrombocytopenia, particularly granulocytes. The indications for chemotherapy and prior chemotherapy, behold, the place of bone marrow. The treatment given the necessary support for your diet. When chemotherapy every two days should be a routine every day if necessary. The white blood cells, granulocytes, particularly reduced, thus increasing the likelihood of infection. In neutropenic patients Ⅲ Ⅳ protective isolation in a separate component could be dispensed with strict aseptic techniques, and the disinfectant bed next to subcutaneous recombinant human granulocyte colony stimulating factor type colonies. Reduce visits, close monitoring of body temperature, if necessary, preventive treatment with antibiotics, blood cultures.

Chemotherapeutic agents can cause nausea, vomiting, diarrhea and other gastrointestinal symptoms. Ward saved some fresh air, reduce support requests. Chemotherapy is usually 5 - HT3 receptor antagonists (eg hydrochloric acid, Joan tropisetron, granisetron, Joan), nausea, vomiting, in severe cases, intravenous hydration. The syndrome of acetylcholine, especially if the drug or once every 24 hours after diarrhea, abdominal pain, sweating, salivation, blurred vision, tearing, vision or other. The first of irinotecan in patients with acute syndrome of acetylcholine before the next use of prophylactic atropine. After infusion of irinotecan, diarrhea, abdominal pain, sweating, salivation, blurred vision, tearing, vision or other symptoms were observed in any of these symptoms should see a doctor to provide treatment.

During the time in treatment of small cell lung cancer with irinotecan combined with cisplatin, close observation of patients and their adverse reactions are necessary. People should enhancing the patient's psychological care and strengthen the medication guidance or health education. The workers need to explain the drug's adverse reactions and make patients understand their disease and strengthen their confidence in order to reduce fear and anxiety of patients on chemotherapy. Clinical validation shows that detailed elaborate care has significantly effects on adverse effect‘s prevention and mitigation. They ensure the smooth progress of chemotherapy and achieve satisfactory results. Source: